Teva Pharmaceutical Industries, Ltd., has been granted FDA approval for a generic formulation of mitoxantrone hydrochloride injection, 2 mg/mL. The drug is indicated for use in combination with corticosteroids as initial therapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.